With its conference call today, Valeant Pharma (NYSE: VRX) said it doesn't have contingency plans if the stock keeps falling and it will sustain a short-term hit in its dermatology business.

CEO Michael Pearson also the company "is going to survive" and this is a "difficult" period for shareholders and the company.

Shares of Valeant are modestly lower in early trading. For more commentary from today's call, click here.

Guidance Management Comments Trader Talk

UPDATE: Eventually Valeant (VRX) Fundamentals Will Matter Again - UBSNovember 11, 2015 9:44 AM Valeant Pharma (VRX) to Employ Drug Discounting Strategy in Effort to 'Protect Volume'November 11, 2015 7:22 AM Valeant (VRX) 'Conservative Base Case' Suggests 109% Upside - NomuraNovember 11, 2015 7:20 AM Valeant Pharma (VRX) Moves Solidly Into the Green, Erasing 7.5% LossNovember 10, 2015 2:01 PM BMO 'Incrementally Positive' on Valeant (VRX) Following Conf. Call; Still See N-T Headline Risk Affecting SharesNovember 10, 2015 10:57 AM Drugmaker Valeant to feel sting of closing controversial pharmacyNovember 10, 2015 8:26 AM UPDATE: Valeant Pharma (VRX) Sees Negative Q4 Impact from Recent Events; Will Issue New Guidance in Dec.November 10, 2015 8:08 AM